The Hidden Cost of Keeping Too Many Options Open

Why focus becomes a leadership task in diagnostics startups

By Dr. Holger Engel

August 2026


Why focus becomes a leadership task in diagnostics startups

Optionality is valuable in an early-stage venture.

A platform may support several applications. A technology may address different customer groups. Multiple product configurations, partnerships or regulatory routes may still appear feasible. Preserving these options can be sensible while the company is learning.

But optionality has a cost.

Every option that remains active consumes attention, development capacity and management time. It creates additional technical dependencies, open questions and future decisions. At some point, flexibility stops being an advantage and begins to slow the company down.

This transition is often difficult to recognise because the organisation still looks active. Teams continue developing, testing and discussing opportunities. Yet evidence accumulates too slowly, priorities become less clear and the path towards a robust product becomes increasingly difficult to explain.

In resource-constrained diagnostics ventures, focus is therefore not simply a matter of efficiency. It is a leadership responsibility.


Every strategic option that remains active is also an operational commitment.


1. Optionality is valuable — until it delays decisions

Keeping options open is often presented as prudent strategy.


It reduces the perceived risk of committing too early. If one application becomes less attractive, another may still succeed. If one technical route proves difficult, a second concept remains available.


This logic is valid during exploration.


The problem begins when the company lacks clear criteria for closing options.


A decision is postponed because more data would be helpful. Another application remains active because a potential partner expressed interest. A second product concept continues because the team has already invested time in it. Gradually, temporary alternatives become permanent workstreams.


The organisation then preserves optionality without defining when or how choices will be made.

Strong development programmes therefore require explicit decision points:


  • What evidence is needed to continue an option?
  • What result would cause us to stop?
  • By when must the decision be made?
  • Who owns the decision?
  • What resources remain committed until then?



Without these boundaries, optionality easily becomes avoidance.

2. Every additional option creates real development work

An additional application is rarely just another assay, cartridge or software configuration.

It may introduce different requirements for:


  • sample type and preparation,
  • analytical performance,
  • workflow and usability,
  • instrument configuration,
  • consumables,
  • manufacturing,
  • quality controls,
  • regulatory strategy,
  • service and support,
  • cost of goods.


The effect is cumulative.


One additional option may appear manageable. Several parallel options can change the entire system architecture and generate a rapidly growing number of dependencies.


This creates a common mismatch between strategic language and operational reality.


At management level, the company may describe itself as “keeping several routes open”. At development level, teams are maintaining multiple specifications, test plans, prototypes and supplier discussions.


Optionality therefore needs to be assessed not only by its strategic potential, but also by its operational cost.


A useful question is:

If we keep this option active, what concrete work are we committing the organisation to perform?


The answer is often larger than expected.


3.Too many paths dilute evidence and slow progress

Startups create value by reducing uncertainty.


This requires evidence.


A development programme should continuously answer critical questions:


  • Does the technology perform reliably?
  • Is the intended workflow feasible?
  • Can the system be manufactured?
  • Are key risks under control?
  • Does the product meet the required performance and cost targets?
  • Is the company ready to commit to the next stage?


When resources are spread across too many options, each route receives less attention. Experiments take longer. Prototypes remain less mature. Decisions are based on incomplete datasets. None of the options reaches the level of evidence required for a confident commitment.


The organisation remains busy, but progress becomes shallow.


This is especially dangerous before fundraising, partnering or strategic reviews. Investors and partners usually do not need to see every conceivable future application. They need confidence that the company can execute a credible path towards a valuable product.


A focused programme often creates more strategic value than a broad platform story supported by limited evidence.

“Investors back credible focus, not unlimited possibilities”


A wide opportunity space can be attractive.

It may demonstrate platform potential and long-term strategic value.


But investors also evaluate whether the management team can translate opportunity into execution.


4. Investors back credible focus, not unlimited possibilities

A wide opportunity space can be attractive.

It may demonstrate platform potential and long-term strategic value. But investors also evaluate whether the management team can translate opportunity into execution.

Too many simultaneously active directions can create difficult questions:


  • Which product is the real priority?
  • What will the current financing round achieve?
  • Which milestone materially reduces risk?
  • How are resources allocated?
  • What will the company stop doing if timelines slip?
  • Which option has the strongest supporting evidence?

When these questions cannot be answered clearly, breadth begins to undermine credibility.


Investors generally understand that future opportunities exist. They do not necessarily expect all of them to be developed at the same time.


A strong financing story can therefore separate two things:


The current development programme

The product, evidence and milestones that the company is actively financing and executing.


The future opportunity pipeline

Applications and expansion routes that remain strategically interesting but are not currently consuming material development resources.


This separation protects optionality without allowing it to weaken execution.

5.Leadership means deciding what not to do

Focus is often discussed as a project-management issue.

In reality, it is a leadership issue.

Teams rarely stop activities voluntarily. Specialists naturally continue improving their part of the system. Founders remain attached to opportunities that originally motivated the company. Business-development discussions create new possibilities. External stakeholders add further requests.

Without active leadership, workstreams accumulate.

The difficult decisions are therefore not only:

  • What should we start?
  • What could create value?
  • Which opportunity looks attractive?


They are also:

  • What will we stop?
  • What will we postpone?
  • Which application is outside the current programme?
  • Which technical improvement is not necessary for the next milestone?
  • Which partnership does not justify diverting the team?
  • Which decision can no longer be delayed?


Saying no does not mean that an opportunity has no value.


It means recognising that the organisation cannot execute every valuable opportunity simultaneously.


In a constrained venture, focus is not the absence of ambition. It is the mechanism that converts ambition into progress.


Focus does not mean ignoring the future

A focused development strategy should not destroy strategic flexibility.


The company can preserve future options through:


  • documented opportunity assessments,
  • clearly defined decision gates,
  • modular architecture where justified,
  • intellectual-property protection,
  • lightweight feasibility work,
  • partnerships that do not distract the core team,
  • periodic strategic reviews.


The important distinction is between an option that remains visible and an option that remains operationally active.

Not every future opportunity needs to receive current development resources.

This allows the company to retain strategic awareness while concentrating execution on the evidence that matters now.


Questions leadership teams should ask

A useful portfolio review does not need to become a major strategy exercise.


It can begin with a few direct questions:


  1. What is the primary product we are currently building?
  2. Which evidence must we generate in the next six to twelve months?
  3. Which active workstreams directly support that objective?
  4. Which options are consuming resources without a defined decision point?
  5. What would we stop if our available capacity fell by 20 percent?
  6. Are future opportunities clearly separated from the funded development programme?
  7. Which decisions are being postponed because they are uncomfortable rather than because more evidence is genuinely required?


The answers often reveal that the main bottleneck is not a lack of ideas.


It is the absence of sufficiently explicit choices.


From optionality to focused execution

Early-stage diagnostics companies need strategic flexibility.


But they also need momentum, evidence and credibility.

The goal is not to eliminate every alternative. It is to manage alternatives deliberately and prevent them from becoming uncontrolled operational commitments.


When priorities are clear:

  • resources are used more effectively,
  • teams understand what matters,
  • technical evidence accumulates faster,
  • roadmaps become more credible,
  • investors can evaluate progress more clearly,
  • the organisation increases its ability to execute.


The central leadership task is therefore not to keep every possibility alive.


It is to decide which possibility deserves the company’s limited time, capital and attention now.


I work with founders, development teams and investors in diagnostics and life science tools to structure complex development programmes, clarify priorities and move technologies towards robust products and viable ventures.


If your organisation is facing difficult portfolio, productization or execution decisions, contact me at info@holgerengel.com, send me a Whatsapp at +4915256345688 or connect with me on LinkedIn.